The lack of a relationship between physician payments from drug manufacturers and Medicare claims for abiraterone and enzalutamide.
Jathin BandariOmar M AyyashRobert M TurnerBruce L JacobsBenjamin J DaviesPublished in: Cancer (2017)
No difference in prescription count was found to exist between prescribers who received industry payments and those who did not. A positive correlation was noted between industry payments and prescription count for enzalutamide. Ease of adoption may affect differences between the 2 drugs. Cancer 2017;123:4356-62. © 2017 American Cancer Society.